X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs DR. REDDYS LAB - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA DR. REDDYS LAB ASTRAZENECA PHARMA/
DR. REDDYS LAB
 
P/E (TTM) x 105.4 29.2 360.3% View Chart
P/BV x 15.0 2.9 523.7% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 ASTRAZENECA PHARMA   DR. REDDYS LAB
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
DR. REDDYS LAB
Mar-17
ASTRAZENECA PHARMA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1,2853,397 37.8%   
Low Rs6342,560 24.8%   
Sales per share (Unadj.) Rs189.6856.5 22.1%  
Earnings per share (Unadj.) Rs-0.278.0 -0.3%  
Cash flow per share (Unadj.) Rs3.8139.9 2.7%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %00.7 0.0%  
Book value per share (Unadj.) Rs68.6739.8 9.3%  
Shares outstanding (eoy) m25.00165.74 15.1%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x5.13.5 145.5%   
Avg P/E ratio x-4,712.738.2 -12,335.6%  
P/CF ratio (eoy) x249.621.3 1,172.4%  
Price / Book Value ratio x14.04.0 347.2%  
Dividend payout %025.7 0.0%   
Avg Mkt Cap Rs m23,988493,632 4.9%   
No. of employees `0001.622.7 6.9%   
Total wages/salary Rs m1,60531,068 5.2%   
Avg. sales/employee Rs Th3,040.26,259.0 48.6%   
Avg. wages/employee Rs Th1,029.21,369.8 75.1%   
Avg. net profit/employee Rs Th-3.3569.7 -0.6%   
INCOME DATA
Net Sales Rs m4,740141,961 3.3%  
Other income Rs m921,715 5.4%   
Total revenues Rs m4,832143,676 3.4%   
Gross profit Rs m-13024,722 -0.5%  
Depreciation Rs m10110,266 1.0%   
Interest Rs m0634 0.0%   
Profit before tax Rs m-13915,537 -0.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m0349 0.0%   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m52,965 0.2%   
Profit after tax Rs m-512,921 -0.0%  
Gross profit margin %-2.717.4 -15.7%  
Effective tax rate %-3.719.1 -19.2%   
Net profit margin %-0.19.1 -1.2%  
BALANCE SHEET DATA
Current assets Rs m2,72696,837 2.8%   
Current liabilities Rs m2,43584,199 2.9%   
Net working cap to sales %6.18.9 69.1%  
Current ratio x1.11.2 97.4%  
Inventory Days Days7473 100.5%  
Debtors Days Days4198 41.7%  
Net fixed assets Rs m1,035102,552 1.0%   
Share capital Rs m50829 6.0%   
"Free" reserves Rs m942121,792 0.8%   
Net worth Rs m1,716122,621 1.4%   
Long term debt Rs m05,449 0.0%   
Total assets Rs m4,156218,165 1.9%  
Interest coverage xNM25.5-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.10.7 175.3%   
Return on assets %-0.16.2 -2.0%  
Return on equity %-0.310.5 -2.8%  
Return on capital %012.9 0.0%  
Exports to sales %5.754.6 10.4%   
Imports to sales %6.59.4 69.1%   
Exports (fob) Rs m27077,520 0.3%   
Imports (cif) Rs m30613,274 2.3%   
Fx inflow Rs m37581,670 0.5%   
Fx outflow Rs m47026,355 1.8%   
Net fx Rs m-9655,315 -0.2%   
CASH FLOW
From Operations Rs m-821,444 -0.0%  
From Investments Rs m-146-18,404 0.8%  
From Financial Activity Rs m862-3,692 -23.4%  
Net Cashflow Rs m709-1,144 -61.9%  

Share Holding

Indian Promoters % 0.0 25.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 5.4 5.6%  
FIIs % 15.7 35.3 44.5%  
ADR/GDR % 0.0 18.5 -  
Free float % 9.1 15.3 59.5%  
Shareholders   12,856 75,885 16.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Rising Dollar after Fed Minutes; F&O Expiry and Top Stocks in Action Today(Pre-Open)

Indian share markets ended largely flat on Thursday following the expiry of derivative contracts for February series. The S&P BSE Sensex ended down by 25 points.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Feb 22, 2018 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - BIOCON LTD COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS